2023-09-012024-08-312024-08-31false08180824HESSINGTON HEALTH LIMITED2025-04-28falseiso4217:GBPxbrli:pure081808242023-09-01081808242024-08-31081808242023-09-012024-08-31081808242022-09-01081808242023-08-31081808242022-09-012023-08-3108180824bus:SmallEntities2023-09-012024-08-3108180824bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3108180824bus:AbridgedAccounts2023-09-012024-08-3108180824bus:PrivateLimitedCompanyLtd2023-09-012024-08-3108180824core:WithinOneYear2024-08-3108180824core:AfterOneYear2024-08-3108180824core:WithinOneYear2023-08-3108180824core:AfterOneYear2023-08-3108180824core:ShareCapital2024-08-3108180824core:SharePremium2024-08-3108180824core:RevaluationReserve2024-08-3108180824core:OtherReservesSubtotal2024-08-3108180824core:RetainedEarningsAccumulatedLosses2024-08-3108180824core:ShareCapital2023-08-3108180824core:SharePremium2023-08-3108180824core:RevaluationReserve2023-08-3108180824core:OtherReservesSubtotal2023-08-3108180824core:RetainedEarningsAccumulatedLosses2023-08-3108180824core:LandBuildings2024-08-3108180824core:PlantMachinery2024-08-3108180824core:Vehicles2024-08-3108180824core:FurnitureFittings2024-08-3108180824core:OfficeEquipment2024-08-3108180824core:NetGoodwill2024-08-3108180824core:IntangibleAssetsOtherThanGoodwill2024-08-3108180824core:ListedExchangeTraded2024-08-3108180824core:UnlistedNon-exchangeTraded2024-08-3108180824core:LandBuildings2023-08-3108180824core:PlantMachinery2023-08-3108180824core:Vehicles2023-08-3108180824core:FurnitureFittings2023-08-3108180824core:OfficeEquipment2023-08-3108180824core:NetGoodwill2023-08-3108180824core:IntangibleAssetsOtherThanGoodwill2023-08-3108180824core:ListedExchangeTraded2023-08-3108180824core:UnlistedNon-exchangeTraded2023-08-3108180824core:LandBuildings2023-09-012024-08-3108180824core:PlantMachinery2023-09-012024-08-3108180824core:Vehicles2023-09-012024-08-3108180824core:FurnitureFittings2023-09-012024-08-3108180824core:OfficeEquipment2023-09-012024-08-3108180824core:NetGoodwill2023-09-012024-08-3108180824core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3108180824core:ListedExchangeTraded2023-09-012024-08-3108180824core:UnlistedNon-exchangeTraded2023-09-012024-08-3108180824core:MoreThanFiveYears2023-09-012024-08-3108180824core:Non-currentFinancialInstruments2024-08-3108180824core:Non-currentFinancialInstruments2023-08-3108180824dpl:CostSales2023-09-012024-08-3108180824dpl:DistributionCosts2023-09-012024-08-3108180824core:LandBuildings2023-09-012024-08-3108180824core:PlantMachinery2023-09-012024-08-3108180824core:Vehicles2023-09-012024-08-3108180824core:FurnitureFittings2023-09-012024-08-3108180824core:OfficeEquipment2023-09-012024-08-3108180824dpl:AdministrativeExpenses2023-09-012024-08-3108180824core:NetGoodwill2023-09-012024-08-3108180824core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3108180824dpl:GroupUndertakings2023-09-012024-08-3108180824dpl:ParticipatingInterests2023-09-012024-08-3108180824dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3108180824core:ListedExchangeTraded2023-09-012024-08-3108180824dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3108180824core:UnlistedNon-exchangeTraded2023-09-012024-08-3108180824dpl:CostSales2022-09-012023-08-3108180824dpl:DistributionCosts2022-09-012023-08-3108180824core:LandBuildings2022-09-012023-08-3108180824core:PlantMachinery2022-09-012023-08-3108180824core:Vehicles2022-09-012023-08-3108180824core:FurnitureFittings2022-09-012023-08-3108180824core:OfficeEquipment2022-09-012023-08-3108180824dpl:AdministrativeExpenses2022-09-012023-08-3108180824core:NetGoodwill2022-09-012023-08-3108180824core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3108180824dpl:GroupUndertakings2022-09-012023-08-3108180824dpl:ParticipatingInterests2022-09-012023-08-3108180824dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3108180824core:ListedExchangeTraded2022-09-012023-08-3108180824dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3108180824core:UnlistedNon-exchangeTraded2022-09-012023-08-3108180824core:NetGoodwill2024-08-3108180824core:IntangibleAssetsOtherThanGoodwill2024-08-3108180824core:LandBuildings2024-08-3108180824core:PlantMachinery2024-08-3108180824core:Vehicles2024-08-3108180824core:FurnitureFittings2024-08-3108180824core:OfficeEquipment2024-08-3108180824core:AfterOneYear2024-08-3108180824core:WithinOneYear2024-08-3108180824core:ListedExchangeTraded2024-08-3108180824core:UnlistedNon-exchangeTraded2024-08-3108180824core:ShareCapital2024-08-3108180824core:SharePremium2024-08-3108180824core:RevaluationReserve2024-08-3108180824core:OtherReservesSubtotal2024-08-3108180824core:RetainedEarningsAccumulatedLosses2024-08-3108180824core:NetGoodwill2023-08-3108180824core:IntangibleAssetsOtherThanGoodwill2023-08-3108180824core:LandBuildings2023-08-3108180824core:PlantMachinery2023-08-3108180824core:Vehicles2023-08-3108180824core:FurnitureFittings2023-08-3108180824core:OfficeEquipment2023-08-3108180824core:AfterOneYear2023-08-3108180824core:WithinOneYear2023-08-3108180824core:ListedExchangeTraded2023-08-3108180824core:UnlistedNon-exchangeTraded2023-08-3108180824core:ShareCapital2023-08-3108180824core:SharePremium2023-08-3108180824core:RevaluationReserve2023-08-3108180824core:OtherReservesSubtotal2023-08-3108180824core:RetainedEarningsAccumulatedLosses2023-08-3108180824core:NetGoodwill2022-09-0108180824core:IntangibleAssetsOtherThanGoodwill2022-09-0108180824core:LandBuildings2022-09-0108180824core:PlantMachinery2022-09-0108180824core:Vehicles2022-09-0108180824core:FurnitureFittings2022-09-0108180824core:OfficeEquipment2022-09-0108180824core:AfterOneYear2022-09-0108180824core:WithinOneYear2022-09-0108180824core:ListedExchangeTraded2022-09-0108180824core:UnlistedNon-exchangeTraded2022-09-0108180824core:ShareCapital2022-09-0108180824core:SharePremium2022-09-0108180824core:RevaluationReserve2022-09-0108180824core:OtherReservesSubtotal2022-09-0108180824core:RetainedEarningsAccumulatedLosses2022-09-0108180824core:AfterOneYear2023-09-012024-08-3108180824core:WithinOneYear2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3108180824core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3108180824core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3108180824core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3108180824core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3108180824core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3108180824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3108180824core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3108180824core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3108180824core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3108180824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3108180824core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3108180824bus:Director12023-09-012024-08-3108180824bus:Director22023-09-012024-08-31

HESSINGTON HEALTH LIMITED

Registered Number
08180824
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

HESSINGTON HEALTH LIMITED
Company Information
for the year from 1 September 2023 to 31 August 2024

Directors

RAI, Harjeev Singh, Dr
RAI, Harpreet Kaur

Registered Address

Grove House
2 Woodberry Grove
London
N12 0DR

Registered Number

08180824 (England and Wales)
HESSINGTON HEALTH LIMITED
Balance Sheet as at
31 August 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets34,1094,386
Tangible assets470,26739,798
74,37644,184
Current assets
Debtors74,1367,113
Cash at bank and on hand168,058202,030
242,194209,143
Creditors amounts falling due within one year5(75,917)(56,303)
Net current assets (liabilities)166,277152,840
Total assets less current liabilities240,653197,024
Creditors amounts falling due after one year(5,958)-
Provisions for liabilities-(365)
Net assets234,695196,659
Capital and reserves
Called up share capital100100
Profit and loss account234,595196,559
Shareholders' funds234,695196,659
The financial statements were approved and authorised for issue by the Board of Directors on 28 April 2025, and are signed on its behalf by:
RAI, Harjeev Singh, Dr
Director
Registered Company No. 08180824
HESSINGTON HEALTH LIMITED
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page. The presentation currency of the financial statements is the Pound Sterling (£).
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. Patents and licences are being amortised evenly over their estimated useful life of twenty years.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
Finance leases and hire purchase contracts
Assets held under finance leases which are leases where substantially all the risks and rewards of ownership of the asset have passed to the company, and hire purchase contracts are capitalised in the balance sheet. They are depreciated over the shorter of their useful lives or the term of the lease.
2.Average number of employees

20242023
Average number of employees during the year33
3.Intangible assets

Total

£
Cost or valuation
At 01 September 235,529
At 31 August 245,529
Amortisation and impairment
At 01 September 231,143
Charge for year277
At 31 August 241,420
Net book value
At 31 August 244,109
At 31 August 234,386
4.Tangible fixed assets

Total

£
Cost or valuation
At 01 September 2373,649
Additions64,999
Disposals(41,500)
At 31 August 2497,148
Depreciation and impairment
At 01 September 2333,852
Charge for year3,923
On disposals(10,894)
At 31 August 2426,881
Net book value
At 31 August 2470,267
At 31 August 2339,798
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables3,1793,766
Taxation and social security8,16316,392
Finance lease and HP contracts6,500-
Other creditors58,07534,558
Accrued liabilities and deferred income-1,587
Total75,91756,303
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
6.Related party transactions
During the year, total dividends of £Nil (2023 - £Nil) were paid to the directors. Other creditors include amounts owed to the directors of £58,075 (2023 : £34,558). These loans are interest free with no fixed date for repayment.